Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT003-QbG10 in Persistent Allergic Asthma: Double-blind, Placebo-controlled Phase IIa Trial
2008-006927-29Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Dec 2008
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing CYT003-QbG10 with Placebo (2 arms). Primary endpoint: Inflammatory parameters. Started Dec 2008; status: completed.
02
Drugs
CYT003-QbG10
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2008-006927-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006927-29.